Brought to you by 
Astellas develops antibodies using Regeneron's VelocImmune
Apr 2007
Executive Summary
Regeneron Pharmaceuticals (clinical candidates for inflammatory, ophthalmic, and oncologic diseases) has licensed Japanese company Astellas Pharma nonexclusive rights to its VelocImmune technology. Astellas will use the platform to discover human monoclonal antibodies.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas develops antibodies using Regeneron's VelocImmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice